Nuvalent Revenue and Competitors

Boston, MA USA

Location

$185M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nuvalent's estimated annual revenue is currently $7.8M per year.(i)
  • Nuvalent's estimated revenue per employee is $88,068
  • Nuvalent's total funding is $185M.
  • Nuvalent's current valuation is $613.2M. (January 2022)

Employee Data

  • Nuvalent has 88 Employees.(i)
  • Nuvalent grew their employee count by 47% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.

keywords:N/A

$185M

Total Funding

88

Number of Employees

$7.8M

Revenue (est)

47%

Employee Growth %

$613.2M

Valuation

N/A

Accelerator

Nuvalent News

2022-04-06 - Nuvalent Presents New Data Demonstrating Expanded ...

Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655...

2022-03-30 - Nuvalent Appoints Anna Protopapas as Chair of Board of ...

CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical stage biopharmaceutical company creating precisely...

2022-03-30 - Nuvalent Reports Pipeline and Business Progress and Fourth ...

Nuvalent plans to initiate the ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive non-small cell lung cancer (NSCLC)...

2021-09-08 - Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent pipeline and business highlights and second quarter 2021 financial ...

2021-05-11 - Nuvalent Closes $135M Series B Financing

Nuvalent, Inc., a Cambridge, Mass.-based biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, closed a $135m Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Manag ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.7M88-16%N/A
#2
$21.4M889%N/A
#3
$12.9M89N/AN/A
#4
$12.5M895%N/A
#5
$13.8M89-4%$57.2M